Tiziana Life Sciences Announces Purchase of Shares by Chairman

Tiziana Life Sciences (NASDAQ:TLSA), a biotechnology company focused on immunomodulation therapies, announced that its Executive Chairman and Founder Gabriele Cerrone has increased his stake in the company through a share purchase.

Rhea-AI Summary

Tiziana Life Sciences (NASDAQ:TLSA), a biotechnology company focused on immunomodulation therapies, announced that its Executive Chairman and Founder Gabriele Cerrone has increased his stake in the company through a share purchase. Cerrone acquired 25,000 common shares at $1.60 per share, bringing his total holdings to 43,277,143 shares, representing 36.28% of the company's issued share capital.

Positive

• Executive Chairman demonstrates confidence in company by investing $40,000 in shares
• Insider now holds significant 36.28% ownership stake in the company

Negative

• None.

Argus Sep 5 session

+5.06% close to close Open Argus

Details

News Market Reaction – TLSA

On Sep 5, the day this news came out, TLSA closed 5.06% above the previous close.

Data tracked by StockTitan Argus for the Sep 5 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 25,000 common shares at $1.60 per share, bringing his total holding to 43,277,143 common shares, which is 36.28% of issued share capital.

About Foralumab

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November of 2023. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.^[1],[2]

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

For further inquiries:

Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

[1] https://www.pnas.org/doi/10.1073/pnas.2220272120

[2] https://www.pnas.org/doi/10.1073/pnas.2309221120

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Tiziana Life Sciences (TLSA) Chairman purchase in September 2025?

Executive Chairman Gabriele Cerrone purchased 25,000 common shares at $1.60 per share, representing a $40,000 investment.

What percentage of Tiziana Life Sciences does Chairman Gabriele Cerrone own after the share purchase?

After the purchase, Gabriele Cerrone owns 43,277,143 common shares, representing 36.28% of the company's issued share capital.

What is Tiziana Life Sciences' (TLSA) main product candidate?

Tiziana's lead development candidate is intranasal foralumab, a fully human, anti-CD3 monoclonal antibody for immunomodulation therapy.

What is the significance of TLSA Chairman's share purchase in September 2025?

The purchase demonstrates insider confidence in the company, with the Executive Chairman increasing his already substantial ownership position to 36.28% of the company.